The Medical Letter on Drugs and Therapeutics
Siltuximab (Sylvant) for Treatment of Multicentric Castleman's Disease (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the interleukin-6 (IL-6) antagonist siltuximab (Sylvant – Janssen), a recombinant chimeric (human-mouse) monoclonal antibody, for treatment of multicentric Castleman's disease (MCD) in patients who are HIV negative and human herpesvirus-8 (HHV-8) negative. It is the first drug to be approved for this indication.

MULTICENTRIC CASTLEMAN'S DISEASE — MCD is a rare lymphoproliferative disorder that is associated with excessive release of IL-6 and other proinflammatory cytokines.1 HHV-8 causes the elevated levels of cytokines in many patients with MCD, particularly those who are HIV positive. The etiology of HIV- and HHV-8-negative MCD is unknown.2 Patients usually present with generalized lymphadenopathy, which may be accompanied by hepatosplenomegaly in severe cases. There is no standard treatment for MCD. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Siltuximab (Sylvant) for Treatment of Multicentric Castleman's Disease (online only)
Article code: 1459f
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian